The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bayer (Inst); EUSA Pharma (Inst)
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Norgine (Inst); Novartis (Inst); Shionogi (Inst)
Patents, Royalties, Other Intellectual Property - Member of SIOPEN Executive Committee, SIOPEN receives royalties for the sales of dinutuximab beta (Inst)
Recommended phase 2 dose (RP2D) for abemaciclib in combination with irinotecan (IRN) and temozolomide (TMZ) in pediatric patients with relapsed/refractory solid tumors (JPCS Part A).
 
Álvaro Lassaletta
Stock and Other Ownership Interests - Gilead Sciences
Consulting or Advisory Role - Alexion Pharmaceuticals; Jazz Pharmaceuticals; SERVIER
 
Lucas Moreno
No Relationships to Disclose
 
Chitose Ogawa
Honoraria - Chugai Pharma
Consulting or Advisory Role - Kyowa Kirin Co., Ltd.; Pfizer
Speakers' Bureau - Ohara Pharmaceutical
Research Funding - Ono Pharmaceutical (Inst)
 
Antonio Ruggiero
Consulting or Advisory Role - AstraZeneca
 
Lindsey M. Hoffman
Consulting or Advisory Role - Lilly O.
 
Celine Pitou
Employment - Lilly O.
Stock and Other Ownership Interests - Lilly O.
 
Yanhong Zhou
Employment - Abbvie; Lilly O.
Stock and Other Ownership Interests - Abbvie; Lilly O.
Travel, Accommodations, Expenses - Lilly O.
 
Molly C. Hardebeck
Employment - Lilly O.
Stock and Other Ownership Interests - Lilly O.
 
Holly Knoderer
Employment - Lilly O.
Stock and Other Ownership Interests - Lilly O.
 
Antonio Juan-Ribelles
No Relationships to Disclose